Super Return Conference, Starboard Opposes Bristol-Celgene Deal, Downside to Trade Deal

Bruce Flatt, CEO at Brookfield Asset Management, discusses opportunities in private equity and the impact of Brexit from the Super Return conference in Berlin. Scott Deveau, Bloomberg News Deals Reporter, explains why activist investor Starboard Value said it will vote against the record pharmaceutical merger of Bristol-Myers Squibb and Celgene, launching a shareholder campaign that could gather dissidents who want to block the deal. Shawn Donnan, Bloomberg News Trade Reporter, talks about his story for Businessweek Magazine on why the global trade regime could suffer from a U.S.-China trade agreement. Michael Arougheti, CEO at Ares Capital Management, discusses competition in the private credit market from the Super Return conference in Berlin. And we Drive to the Close of markets with Rick Bensignor, President Bensignor Investment Strategies. Hosts: Carol Massar and Jason Kelly. Producer: Paul Brennan 

2356 232